Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

LENZ

LENZ Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · SIC 2836CIK 1815776Held by 1 tracked managerEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$19.0M
Net Income FY2025
$(82.0M)
EPS (Basic, as reported)
$-2.85
Net Margin FY2025
-430.3%
ROE FY2025
-28.9%
Total Equity
$284.0M
Shares Out
31M
Business description

LENZ Therapeutics, Inc. — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2020–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 0 → 19
Fiscal yearFY2020FY2021⚑FY2022FY2023⚑FY2024FY2025
Revenue————019
Cost of revenue————00
Research & development(9)(38)(73)(32)(30)(19)
Selling, general & administrative———(13)(29)(91)
General & administrative(4)(23)(33)(41)——
Total operating expenses(13)(60)(106)(135)(59)(110)
Operating income(13)(60)(106)(135)(59)(91)
Interest & investment income———2910
Other income (expense), net(55)(10)511910
Pre-tax income———(70)(50)(82)
Income tax expense00000(1)
Net income(68)(71)(101)(125)(50)(82)
EPS — basic—($2.45)($1.84)($2.19)($2.34)($2.85)
EPS — diluted—($2.45)($1.84)($2.19)($2.34)($2.85)
Shares outstanding — basic (M)—2955572129
Shares outstanding — diluted (M)—2955572129
  • ⚑ Weighted-average shares changed ×1.90 between FY2021 and FY2022 — likely a stock split. Per-share figures on either side are as reported and not adjusted.
  • ⚑ Weighted-average shares changed ÷2.70 between FY2023 and FY2024 — likely a reverse split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.